Healthcare perspectives from The Economist Intelligence Unit
Related content
高まる二次予防の重要性: アジアにおける心疾患医療の現状・課題
国によって状況は異なるものの、心血管疾患(CVD)がもたらす負担が非常に大きいことは間違いない。CVD は全てのアジア諸国で二大死因となっており、患者数も増加の一途を辿っている。またアジアでは、若年層のCVD 患者・高齢者層の合併症患者が並行して増えており、医療体制にさらなる負担をもたらしている。
近年、CVD に関連する問題への対策は、一次予防の分野で進化を遂げつつあり、年齢調整罹患率にも減少の兆しが見られる。しかし急性心筋梗塞・脳卒中の再発率は依然として高く、その経済的・人的コストも大きいのが実状である。また一度目の発症での生存率が向上している今、再発によって生じる負担はさらに増す可能性が高い。ただし、対応が急務となっているこうした現状に取り組むことが現実的であることを鑑みると、当該患者グループのケア体制・アウトカムを向上させる重要な機会だと捉えることができる。
ザ・エコノミスト・インテリジェンス・ユニット(EIU)の本報告書は、アジア太平洋地域8 カ国(オーストラリア・中国・香港・日本・シンガポール・韓国・台湾・タイ)を対象として、CVD の再発予防に向けた政策的取り組みを検証する。
主要な論点は以下の通り:
多くの国はCVD 政策を掲げているが、包括性の面で大きな差がある。 改善可能なリスク因子への取り組みは、具体的な法案・行動計画、および成果評価に必ずしも結びついていない。 政府による成果評価の仕組みは発展途上である。 包括医療に不可欠なプライマリケアは近年進化を遂げつつある。 多くの国はリハビリサービスを実施しているが、提供能力は限られており、利用者も伸び悩んでいる。 連携を通じた患者中心の包括医療の必要性 取り組みの成功の鍵を握るのは患者エンパワーメント データ活用の加速と成果評価の仕組みも重要な鍵となる亚太地区心血管疾病二级预防报告
亚太地区心血管疾病的负担因国家/地区而异,但无论任何国家/地区都负担沉重。总体来说,心血管疾病在该地区是造成死亡的首要或次要原因,其患病率也在不断增长。除此以外,该地区人口结构的变化——患心血管疾病的年轻人增加,同时患有多种合并症的老龄人口也呈增长趋势——令医疗系统越来越不堪重负。
应对心血管疾病相关问题的进展主要集中于一级预防领域,同时心血管疾病年龄标准化患病率也正在降低。然而心脏病和卒中复发的几率长期居高不下,令人难以接受,而与之相关的经济和人力成本亦威胁着已经取得的进步。由于越来越多的患者能在心脏病或卒中首次发病时幸存,复发事件所带来的负担很可能会更加沉重。这一状况需要紧急的关注,但同时也带来了一个非常有可能实现的机遇——改善该患者群体所接受的医疗护理及其效果。
本次由经济学人智库(The Economist Intelligence Unit/The EIU)所做的分析探究了亚太地区在管理心血管疾病复发事件上的政策响应措施,研究主要聚焦于以下八个经济体:澳大利亚、中国大陆、中国香港、中国台湾、日本、新加坡、韩国以及泰国。
本研究主要发现包括:
虽然确实存在心血管疾病政策,但有些政策比其他政策更为全面。 将可改变的风险因素有关的政策落实到立法和行动层面的措施是否成功,以及对其影响的评估方法都有待界定。 缺乏政府审计。 初级医疗系统作为综合医疗的关键组成部分,正在不断升级。 康护服务存在但是覆盖范围有限,同时这些项目很难召集和留住患者。 必需确定以患者为中心的综合、协调医疗护理目标. 患者赋权是成功的制胜法宝. 最大程度推进数据和衡量进度.
조치 부재의 비용: 아시아 태평양 지역 내 심혈관 질환의 2차 예방
아시아 태평양 지역의 심혈관 질환(CVD)부담은 국가별로 상이하나 모두 상당하다.CVD는 지역 전반에서 사망 원인 1위 또는2위를 차지하고 있으며, 유병률도 계속높아지고 있다. 또한 CVD를 경험하는 젊은환자와 여러 동반 이환을 가진 고령화 인구두 집단 모두의 증가라는 지역 내 인구통계적변화로 인해 각국의 보건의료체계에 부하가걸리고 있다.
CVD 관련 문제 해결에 관한 진척은 1차예방 분야에 초점이 맞춰져 이루어져왔으며, CVD의 연령표준화 발생률은감소하기 시작했다. 그러나 여전히 허용할수 없는 높은 수준의 심장마비 및 뇌졸중재발률과 그에 따른 경제적 및 인적 비용이존재해 이러한 진척을 저해하고 있다. 첫심장마비 또는 뇌졸중 생존자가 더많아짐에 따라 2차 사건 관련 부담이증가할 가능성이 높다. 이는 긴급한 주의를요구하는 상황인 동시에, 해당 환자 집단의관리와 결과를 개선할 수 있는 탁월하고현실적인 기회이기도 하다.
Related content
亚太地区心血管疾病二级预防报告
亚太地区心血管疾病的负担因国家/地区而异,但无论任何国家/地区都负担沉重。总体来说,心血管疾病在该地区是造成死亡的首要或次要原因,其患病率也在不断增长。除此以外,该地区人口结构的变化——患心血管疾病的年轻人增加,同时患有多种合并症的老龄人口也呈增长趋势——令医疗系统越来越不堪重负。
应对心血管疾病相关问题的进展主要集中于一级预防领域,同时心血管疾病年龄标准化患病率也正在降低。然而心脏病和卒中复发的几率长期居高不下,令人难以接受,而与之相关的经济和人力成本亦威胁着已经取得的进步。由于越来越多的患者能在心脏病或卒中首次发病时幸存,复发事件所带来的负担很可能会更加沉重。这一状况需要紧急的关注,但同时也带来了一个非常有可能实现的机遇——改善该患者群体所接受的医疗护理及其效果。
本次由经济学人智库(The Economist Intelligence Unit/The EIU)所做的分析探究了亚太地区在管理心血管疾病复发事件上的政策响应措施,研究主要聚焦于以下八个经济体:澳大利亚、中国大陆、中国香港、中国台湾、日本、新加坡、韩国以及泰国。
本研究主要发现包括:
虽然确实存在心血管疾病政策,但有些政策比其他政策更为全面。 将可改变的风险因素有关的政策落实到立法和行动层面的措施是否成功,以及对其影响的评估方法都有待界定。 缺乏政府审计。 初级医疗系统作为综合医疗的关键组成部分,正在不断升级。 康护服务存在但是覆盖范围有限,同时这些项目很难召集和留住患者。 必需确定以患者为中心的综合、协调医疗护理目标. 患者赋权是成功的制胜法宝. 最大程度推进数据和衡量进度.
高まる二次予防の重要性: アジアにおける心疾患医療の現状・課題
国によって状況は異なるものの、心血管疾患(CVD)がもたらす負担が非常に大きいことは間違いない。CVD は全てのアジア諸国で二大死因となっており、患者数も増加の一途を辿っている。またアジアでは、若年層のCVD 患者・高齢者層の合併症患者が並行して増えており、医療体制にさらなる負担をもたらしている。
近年、CVD に関連する問題への対策は、一次予防の分野で進化を遂げつつあり、年齢調整罹患率にも減少の兆しが見られる。しかし急性心筋梗塞・脳卒中の再発率は依然として高く、その経済的・人的コストも大きいのが実状である。また一度目の発症での生存率が向上している今、再発によって生じる負担はさらに増す可能性が高い。ただし、対応が急務となっているこうした現状に取り組むことが現実的であることを鑑みると、当該患者グループのケア体制・アウトカムを向上させる重要な機会だと捉えることができる。
ザ・エコノミスト・インテリジェンス・ユニット(EIU)の本報告書は、アジア太平洋地域8 カ国(オーストラリア・中国・香港・日本・シンガポール・韓国・台湾・タイ)を対象として、CVD の再発予防に向けた政策的取り組みを検証する。
主要な論点は以下の通り:
多くの国はCVD 政策を掲げているが、包括性の面で大きな差がある。 改善可能なリスク因子への取り組みは、具体的な法案・行動計画、および成果評価に必ずしも結びついていない。 政府による成果評価の仕組みは発展途上である。 包括医療に不可欠なプライマリケアは近年進化を遂げつつある。 多くの国はリハビリサービスを実施しているが、提供能力は限られており、利用者も伸び悩んでいる。 連携を通じた患者中心の包括医療の必要性 取り組みの成功の鍵を握るのは患者エンパワーメント データ活用の加速と成果評価の仕組みも重要な鍵となるData and digital technologies to improve clinical outcomes for high-risk ca...
Cardiovascular diseases (CVD) account for around one quarter of deaths in Australia.1 The Economist Intelligence Unit estimates that the annual direct and indirect costs of CVD in Australia totals US$12.3bn.2 There are numerous modifiable risk factors for CVD, but the most important include hypertension (high blood pressure), high cholesterol, tobacco use, diabetes and obesity.3 While much of the recent focus has been on primary prevention through lifestyle modification, those highrisk patients with existing CVD—such as peripheral artery disease or a previous heart attack or stroke—require particular attention to avoid further morbidity and mortality.
The improved use of data and digital health tools has the potential to enable more coordinated and patient-centred models of care. The Digital Health CRC takes this further in saying “research and innovation in digital health offers Australia significant economic and business development opportunities, as well as great promise for the better health of our community”.4
On 27 May 2020, The Economist Intelligence Unit—supported by the Australian Cardiovascular Alliance (ACvA) and Digital Health CRC and with sponsorship from Amgen—convened a virtual roundtable discussion with 25 representatives from across the Australian cardiovascular healthcare landscape.
Co-hosted by the Economist Intelligence Unit with Dr Gemma Figtree, president of ACvA and professor in medicine at University of Sydney & Royal North Shore Hospital, and Dr Tim Shaw, director of research and workforce capacity at Digital Health CRC, the roundtable aimed to identify barriers, challenges and opportunities to improve outcomes for highrisk CVD patients by improving the use of data and digital technologies.
1 Australian Institute of Health and Welfare. Cardiovascular disease. In: Welfare AIoHa, editor. Canberra 2019. 2 Economist Intelligence Unit. “The cost of silence: Cardiovascular disease in Asia”, 2019 3 Centers for Disease Control and Prevention. “Know your risk for heart diseases”. Available from: https://www.cdc.gov/heartdisease/risk_factors.htm (Accessed Jun 2020). 4 Digital Health CRC. “About us”. Available from: https://www.digitalhealthcrc.com/about-us/ (Accesed Jun 2020).
高まる二次予防の重要性: アジアにおける心疾患医療の現状・課題
国によって状況は異なるものの、心血管疾患(CVD)がもたらす負担が非常に大きいことは間違いない。CVD は全てのアジア諸国で二大死因となっており、患者数も増加の一途を辿っている。またアジアでは、若年層のCVD 患者・高齢者層の合併症患者が並行して増えており、医療体制にさらなる負担をもたらしている。
近年、CVD に関連する問題への対策は、一次予防の分野で進化を遂げつつあり、年齢調整罹患率にも減少の兆しが見られる。しかし急性心筋梗塞・脳卒中の再発率は依然として高く、その経済的・人的コストも大きいのが実状である。また一度目の発症での生存率が向上している今、再発によって生じる負担はさらに増す可能性が高い。ただし、対応が急務となっているこうした現状に取り組むことが現実的であることを鑑みると、当該患者グループのケア体制・アウトカムを向上させる重要な機会だと捉えることができる。
ザ・エコノミスト・インテリジェンス・ユニット(EIU)の本報告書は、アジア太平洋地域8 カ国(オーストラリア・中国・香港・日本・シンガポール・韓国・台湾・タイ)を対象として、CVD の再発予防に向けた政策的取り組みを検証する。
主要な論点は以下の通り:
Related content
조치 부재의 비용: 아시아 태평양 지역 내 심혈관 질환의 2차 예방
아시아 태평양 지역의 심혈관 질환(CVD)부담은 국가별로 상이하나 모두 상당하다.CVD는 지역 전반에서 사망 원인 1위 또는2위를 차지하고 있으며, 유병률도 계속높아지고 있다. 또한 CVD를 경험하는 젊은환자와 여러 동반 이환을 가진 고령화 인구두 집단 모두의 증가라는 지역 내 인구통계적변화로 인해 각국의 보건의료체계에 부하가걸리고 있다.
CVD 관련 문제 해결에 관한 진척은 1차예방 분야에 초점이 맞춰져 이루어져왔으며, CVD의 연령표준화 발생률은감소하기 시작했다. 그러나 여전히 허용할수 없는 높은 수준의 심장마비 및 뇌졸중재발률과 그에 따른 경제적 및 인적 비용이존재해 이러한 진척을 저해하고 있다. 첫심장마비 또는 뇌졸중 생존자가 더많아짐에 따라 2차 사건 관련 부담이증가할 가능성이 높다. 이는 긴급한 주의를요구하는 상황인 동시에, 해당 환자 집단의관리와 결과를 개선할 수 있는 탁월하고현실적인 기회이기도 하다.
본 이코노미스트 인텔리전스 유닛분석에서는 아시아 태평양 지역8개국(호주, 중국, 홍콩, 일본, 싱가포르,한국, 대만, 태국)의 2차 심혈관 사건관리에 대한 정책적 대응을 살펴본다. 본 연구의 주요 결과는 다음을 포함한다. 관련 정책은 확실히 존재하나, 정책이상당히 포괄적인 국가도 있고 그렇지 않은국가도 있다. 조절 가능한 위험인자에 대한 정책을 법률과실천에 성공적으로 반영했는지 여부와 그로인한 영향은 아직 확인되지 않았다. 정부 감사가 결여되어 있다. 통합 관리의 핵심 요소인 1차 의료 체계가발전하고 있다. 재활 서비스가 존재하나 보장 범위가제한적이며, 업체들은 환자 유치와 유지에어려움을 겪고 있다. 필요한 목표는 환자 중심의 통합적이고조정된 관리 환자 권한부여는 성공의 핵심 데이터 극대화 및 진척도 측정Data and digital technologies to improve clinical outcomes for high-risk ca...
Cardiovascular diseases (CVD) account for around one quarter of deaths in Australia.1 The Economist Intelligence Unit estimates that the annual direct and indirect costs of CVD in Australia totals US$12.3bn.2 There are numerous modifiable risk factors for CVD, but the most important include hypertension (high blood pressure), high cholesterol, tobacco use, diabetes and obesity.3 While much of the recent focus has been on primary prevention through lifestyle modification, those highrisk patients with existing CVD—such as peripheral artery disease or a previous heart attack or stroke—require particular attention to avoid further morbidity and mortality.
The improved use of data and digital health tools has the potential to enable more coordinated and patient-centred models of care. The Digital Health CRC takes this further in saying “research and innovation in digital health offers Australia significant economic and business development opportunities, as well as great promise for the better health of our community”.4
On 27 May 2020, The Economist Intelligence Unit—supported by the Australian Cardiovascular Alliance (ACvA) and Digital Health CRC and with sponsorship from Amgen—convened a virtual roundtable discussion with 25 representatives from across the Australian cardiovascular healthcare landscape.
Co-hosted by the Economist Intelligence Unit with Dr Gemma Figtree, president of ACvA and professor in medicine at University of Sydney & Royal North Shore Hospital, and Dr Tim Shaw, director of research and workforce capacity at Digital Health CRC, the roundtable aimed to identify barriers, challenges and opportunities to improve outcomes for highrisk CVD patients by improving the use of data and digital technologies.
1 Australian Institute of Health and Welfare. Cardiovascular disease. In: Welfare AIoHa, editor. Canberra 2019. 2 Economist Intelligence Unit. “The cost of silence: Cardiovascular disease in Asia”, 2019 3 Centers for Disease Control and Prevention. “Know your risk for heart diseases”. Available from: https://www.cdc.gov/heartdisease/risk_factors.htm (Accessed Jun 2020). 4 Digital Health CRC. “About us”. Available from: https://www.digitalhealthcrc.com/about-us/ (Accesed Jun 2020).
亚太地区心血管疾病二级预防报告
亚太地区心血管疾病的负担因国家/地区而异,但无论任何国家/地区都负担沉重。总体来说,心血管疾病在该地区是造成死亡的首要或次要原因,其患病率也在不断增长。除此以外,该地区人口结构的变化——患心血管疾病的年轻人增加,同时患有多种合并症的老龄人口也呈增长趋势——令医疗系统越来越不堪重负。
应对心血管疾病相关问题的进展主要集中于一级预防领域,同时心血管疾病年龄标准化患病率也正在降低。然而心脏病和卒中复发的几率长期居高不下,令人难以接受,而与之相关的经济和人力成本亦威胁着已经取得的进步。由于越来越多的患者能在心脏病或卒中首次发病时幸存,复发事件所带来的负担很可能会更加沉重。这一状况需要紧急的关注,但同时也带来了一个非常有可能实现的机遇——改善该患者群体所接受的医疗护理及其效果。
本次由经济学人智库(The Economist Intelligence Unit/The EIU)所做的分析探究了亚太地区在管理心血管疾病复发事件上的政策响应措施,研究主要聚焦于以下八个经济体:澳大利亚、中国大陆、中国香港、中国台湾、日本、新加坡、韩国以及泰国。
本研究主要发现包括:
虽然确实存在心血管疾病政策,但有些政策比其他政策更为全面。 将可改变的风险因素有关的政策落实到立法和行动层面的措施是否成功,以及对其影响的评估方法都有待界定。 缺乏政府审计。 初级医疗系统作为综合医疗的关键组成部分,正在不断升级。 康护服务存在但是覆盖范围有限,同时这些项目很难召集和留住患者。 必需确定以患者为中心的综合、协调医疗护理目标. 患者赋权是成功的制胜法宝. 最大程度推进数据和衡量进度.
The covid-19 push: Accelerating change in Australian industries | Healthcare
Welcome to our first piece in The covid-19 push: Accelerating change in Australian industries.
Created by The Economist Intelligence Unit and sponsored by Vocus, this series looks at how covid-19 has provided a powerful impetus to accelerate innovation and positive change in key industries, enabling them to bring forward significant benefits for customers, communities and the industries themselves.
More from this series
17480
Related content
Value-based healthcare in Sweden: Reaching the next level
The need to get better value from healthcare investment has never been more important as ageing populations and increasing numbers of people with multiple chronic conditions force governments to make limited financial resources go further.
These pressures, along with a greater focus on patient-centred care, have raised the profile of VBHC, especially in European healthcare systems. Sweden, with its highly comprehensive and egalitarian healthcare system, has been a leader in implementing VBHC from the beginning, a fact that was underscored in a 2016 global assessment of VBHC published by The Economist Intelligence Unit.
This paper looks at the ways in which Sweden has implemented VBHC, the areas in which it has faced obstacles and the lessons that it can teach other countries and health systems looking to improve the value of their own healthcare investments.
Breast cancer patients and survivors in the Asia-Pacific workforce
With more older women also working, how will the rising trend of breast cancer survivorship manifest in workplace policies, practices and culture? What challenges do breast cancer survivors face when trying to reintegrate into the workforce, or to continue working during treatment? How can governments, companies and society at large play a constructive role?
This series of reports looks at the situation for breast cancer survivors in Australia, New Zealand and South Korea. It finds that while progress has been made, more needs to be done, particularly in South Korea, where public stigma around cancer remains high.The Cost of Silence
Cardiovascular diseases levy a substantial financial toll on individuals, their households and the public finances. These include the costs of hospital treatment, long-term disease management and recurring incidence of heart attacks and stroke. They also include the costs of functional impairment and knock-on costs as families may lose breadwinners or have to withdraw other family members from the workforce to care for a CVD patient. Governments also lose tax revenue due to early retirement and mortality, and can be forced to reallocate public finances from other budgets to maintain an accessible healthcare system in the face of rising costs.
As such, there is a need for more awareness of the ways in which people should actively work to reduce their CVD risk. There is also a need for more primary and secondary preventative support from health agencies, policymakers and nongovernmental groups.
To inform the decisions and strategies of these stakeholders, The Economist Intelligence Unit and EIU Healthcare, its healthcare subsidiary, have conducted a study of the prevalence and costs of the top four modifiable risk factors that contribute to CVDs across the Asian markets of China, Australia, Hong Kong, Japan, Singapore, South Korea, Taiwan and Thailand.
Download the report to learn more.
Related content
The Cost of Silence: Cardiovascular disease in Asia
The Cost of Silence: Cardiovascular disease in Asia is a report by The Economist Intelligence Unit and EIU Healthcare. It provides a study of the economic impact of CVD risk factors on the following Asian markets: China, Australia, Hong Kong, Japan, Singapore, South Korea, Taiwan and Thailand.
Specifically, the study captures the cost of ischaemic heart disease (IHD) and stroke. IHD, also called coronary heart disease (CHD) or coronary artery disease, is the term given to heart problems caused by narrowed heart (coronary) arteries that supply blood to the heart muscle, which can lead to stable angina, unstable angina, myocardial infarctions or heart attacks, and sudden cardiac death. Stroke is characterised by the sudden loss of blood circulation to an area of the brain due to blockage of brain vessels, or a haemorrhage or blood clot.
This study further combines an evidence review of existing research on CVDs and primary research in the form of expert interviews.
Key findings of the report are as follow:
The rising incidence of CVD poses a substantial challenge to Asia-Pacific markets The four main modifiable cardiovascular risk factors pose a communications challenge for governments and health agencies. Hypertension is the risk factor that contributes the highest cost. The costs of CVDs are not fixed. Greater awareness and policymaker attention can substantially reduce CVD costs as many obstacles and corresponding solutions have been identified as effective. Policy options for primary prevention include choice “nudges”. Effective secondary prevention can also significantly affect costs and outcomes.Demystifying ageing: Lifting the burden of fragility fractures and osteopor...
Fragility fractures are already a significant public health challenge across Asia-Pacific. Their lasting impact on societies and economies is well-documented, leading to loss of mobility, independence and, in some instances, death for their elderly sufferers. In many traditional Asia-Pacific societies, where older people often serve as caregivers for younger generations, fractures can devastate entire families and communities. From a broader perspective, the cost of treating hip fractures to Asia-Pacific societies equates to 19% of GDP per capita, underscoring the enormity of the problem.
As populations age, many believe fragility fractures will become more widespread, yet this is not necessarily the case. Osteoporosis, a condition that makes bones more likely to break and a leading cause of fractures, was within living memory thought to be a natural part of ageing. This myth is gradually being dispelled. The condition is preventable and treatable—a fact which receives too little attention across the region. This study looks at the challenge fragility fractures and osteoporosis pose and how health systems are responding in eight Asia-Pacific economies: Australia, Hong Kong, Japan, New Zealand, Singapore, South Korea, Taiwan and Thailand (called collectively in the text the “scorecard economies”).
Download the report in English | 한국어 | 繁體中文 View the infographic in English | 한국어 | 繁體中文 Fight the Fracture, a public education campaign, aims to empower patients who have suffered a fragility fracture and their caregivers to proactively seek medical professional help in secondary care prevention ‒ the prevention of a subsequent fracture ‒ by providing them with educational information, tools and resources. Find out more about Fight the Fracture at: www.fightthefracture.asia亚太地区心血管疾病二级预防报告
亚太地区心血管疾病的负担因国家/地区而异,但无论任何国家/地区都负担沉重。总体来说,心血管疾病在该地区是造成死亡的首要或次要原因,其患病率也在不断增长。除此以外,该地区人口结构的变化——患心血管疾病的年轻人增加,同时患有多种合并症的老龄人口也呈增长趋势——令医疗系统越来越不堪重负。
应对心血管疾病相关问题的进展主要集中于一级预防领域,同时心血管疾病年龄标准化患病率也正在降低。然而心脏病和卒中复发的几率长期居高不下,令人难以接受,而与之相关的经济和人力成本亦威胁着已经取得的进步。由于越来越多的患者能在心脏病或卒中首次发病时幸存,复发事件所带来的负担很可能会更加沉重。这一状况需要紧急的关注,但同时也带来了一个非常有可能实现的机遇——改善该患者群体所接受的医疗护理及其效果。
本次由经济学人智库(The Economist Intelligence Unit/The EIU)所做的分析探究了亚太地区在管理心血管疾病复发事件上的政策响应措施,研究主要聚焦于以下八个经济体:澳大利亚、中国大陆、中国香港、中国台湾、日本、新加坡、韩国以及泰国。
本研究主要发现包括:
Related content
高まる二次予防の重要性: アジアにおける心疾患医療の現状・課題
国によって状況は異なるものの、心血管疾患(CVD)がもたらす負担が非常に大きいことは間違いない。CVD は全てのアジア諸国で二大死因となっており、患者数も増加の一途を辿っている。またアジアでは、若年層のCVD 患者・高齢者層の合併症患者が並行して増えており、医療体制にさらなる負担をもたらしている。
近年、CVD に関連する問題への対策は、一次予防の分野で進化を遂げつつあり、年齢調整罹患率にも減少の兆しが見られる。しかし急性心筋梗塞・脳卒中の再発率は依然として高く、その経済的・人的コストも大きいのが実状である。また一度目の発症での生存率が向上している今、再発によって生じる負担はさらに増す可能性が高い。ただし、対応が急務となっているこうした現状に取り組むことが現実的であることを鑑みると、当該患者グループのケア体制・アウトカムを向上させる重要な機会だと捉えることができる。
ザ・エコノミスト・インテリジェンス・ユニット(EIU)の本報告書は、アジア太平洋地域8 カ国(オーストラリア・中国・香港・日本・シンガポール・韓国・台湾・タイ)を対象として、CVD の再発予防に向けた政策的取り組みを検証する。
主要な論点は以下の通り:
多くの国はCVD 政策を掲げているが、包括性の面で大きな差がある。 改善可能なリスク因子への取り組みは、具体的な法案・行動計画、および成果評価に必ずしも結びついていない。 政府による成果評価の仕組みは発展途上である。 包括医療に不可欠なプライマリケアは近年進化を遂げつつある。 多くの国はリハビリサービスを実施しているが、提供能力は限られており、利用者も伸び悩んでいる。 連携を通じた患者中心の包括医療の必要性 取り組みの成功の鍵を握るのは患者エンパワーメント データ活用の加速と成果評価の仕組みも重要な鍵となる조치 부재의 비용: 아시아 태평양 지역 내 심혈관 질환의 2차 예방
아시아 태평양 지역의 심혈관 질환(CVD)부담은 국가별로 상이하나 모두 상당하다.CVD는 지역 전반에서 사망 원인 1위 또는2위를 차지하고 있으며, 유병률도 계속높아지고 있다. 또한 CVD를 경험하는 젊은환자와 여러 동반 이환을 가진 고령화 인구두 집단 모두의 증가라는 지역 내 인구통계적변화로 인해 각국의 보건의료체계에 부하가걸리고 있다.
CVD 관련 문제 해결에 관한 진척은 1차예방 분야에 초점이 맞춰져 이루어져왔으며, CVD의 연령표준화 발생률은감소하기 시작했다. 그러나 여전히 허용할수 없는 높은 수준의 심장마비 및 뇌졸중재발률과 그에 따른 경제적 및 인적 비용이존재해 이러한 진척을 저해하고 있다. 첫심장마비 또는 뇌졸중 생존자가 더많아짐에 따라 2차 사건 관련 부담이증가할 가능성이 높다. 이는 긴급한 주의를요구하는 상황인 동시에, 해당 환자 집단의관리와 결과를 개선할 수 있는 탁월하고현실적인 기회이기도 하다.
본 이코노미스트 인텔리전스 유닛분석에서는 아시아 태평양 지역8개국(호주, 중국, 홍콩, 일본, 싱가포르,한국, 대만, 태국)의 2차 심혈관 사건관리에 대한 정책적 대응을 살펴본다. 본 연구의 주요 결과는 다음을 포함한다. 관련 정책은 확실히 존재하나, 정책이상당히 포괄적인 국가도 있고 그렇지 않은국가도 있다. 조절 가능한 위험인자에 대한 정책을 법률과실천에 성공적으로 반영했는지 여부와 그로인한 영향은 아직 확인되지 않았다. 정부 감사가 결여되어 있다. 통합 관리의 핵심 요소인 1차 의료 체계가발전하고 있다. 재활 서비스가 존재하나 보장 범위가제한적이며, 업체들은 환자 유치와 유지에어려움을 겪고 있다. 필요한 목표는 환자 중심의 통합적이고조정된 관리 환자 권한부여는 성공의 핵심 데이터 극대화 및 진척도 측정Data and digital technologies to improve clinical outcomes for high-risk ca...
Cardiovascular diseases (CVD) account for around one quarter of deaths in Australia.1 The Economist Intelligence Unit estimates that the annual direct and indirect costs of CVD in Australia totals US$12.3bn.2 There are numerous modifiable risk factors for CVD, but the most important include hypertension (high blood pressure), high cholesterol, tobacco use, diabetes and obesity.3 While much of the recent focus has been on primary prevention through lifestyle modification, those highrisk patients with existing CVD—such as peripheral artery disease or a previous heart attack or stroke—require particular attention to avoid further morbidity and mortality.
The improved use of data and digital health tools has the potential to enable more coordinated and patient-centred models of care. The Digital Health CRC takes this further in saying “research and innovation in digital health offers Australia significant economic and business development opportunities, as well as great promise for the better health of our community”.4
On 27 May 2020, The Economist Intelligence Unit—supported by the Australian Cardiovascular Alliance (ACvA) and Digital Health CRC and with sponsorship from Amgen—convened a virtual roundtable discussion with 25 representatives from across the Australian cardiovascular healthcare landscape.
Co-hosted by the Economist Intelligence Unit with Dr Gemma Figtree, president of ACvA and professor in medicine at University of Sydney & Royal North Shore Hospital, and Dr Tim Shaw, director of research and workforce capacity at Digital Health CRC, the roundtable aimed to identify barriers, challenges and opportunities to improve outcomes for highrisk CVD patients by improving the use of data and digital technologies.
1 Australian Institute of Health and Welfare. Cardiovascular disease. In: Welfare AIoHa, editor. Canberra 2019. 2 Economist Intelligence Unit. “The cost of silence: Cardiovascular disease in Asia”, 2019 3 Centers for Disease Control and Prevention. “Know your risk for heart diseases”. Available from: https://www.cdc.gov/heartdisease/risk_factors.htm (Accessed Jun 2020). 4 Digital Health CRC. “About us”. Available from: https://www.digitalhealthcrc.com/about-us/ (Accesed Jun 2020).
Two out of three rare disease patients in Asia-Pacific do not receive the best-available care, according to an Economist Intelligence Unit survey
Related content
Suffering in silence: Assessing rare disease awareness and management in As...
As the region begins to get to grips with rare diseases, it will need to address significant challenges, some of which are still emerging. Health and social systems are making progress in many of these areas, but finding solutions remains a work in progress.
This Economist Intelligence Unit study, sponsored by CSL Behring, looks at the nature of the rare disease challenge in the region, how prepared five of its economies are to face it, and reviews the initiatives aiming to provide better care. It draws on a substantial survey of over 500 clinicians, interviews with 16 academic, medical, government and patient experts, and extensive desk research.
In November-December 2019, The Economist Intelligence Unit surveyed 503 healthcare professionals across five Asia-Pacific markets to gauge their understanding of rare diseases and identify the challenges faced by national health systems. Respondents comprised currently practicing specialist physicians (n=172), general practitioners (n=229), nurses (n=40) and pharmacists (n=62). Markets included were Australia (n=103), China (n=100), Japan (n=100), South Korea (n=100) and Taiwan (n=100).
In addition, in-depth contextualising interviews were conducted with 16 expert representatives of clinical practice and patient organisations to inform our research programme and this report. Our sincerest thanks go to the following for their time and insight:
Takeya Adachi, program officer, Agency for Medical Research and Development, Japan Younjhin Ahn, Division of Rare Diseases, Korean National Institute of Health Centre for Biomedical Sciences, South Korea Matthew Bellgard, professor and director of eResearch, Queensland University of Technology, Australia and chair of the Asia Pacific Economic Cooperation (APEC) Rare Disease Network, Australia Gareth Baynam, clinical geneticist and director of the Undiagnosed Diseases Program Genetic Services of Western Australia, Australia Dong Dong, research assistant professor, Chinese University of Hong Kong, Hong Kong SAR Elizabeth Elliott, professor of Paediatrics and Child Health, University of Sydney, Australia Kevin Huang, founder, Chinese Organization for Rare Disorders, China Ritu Jain, president, Asia-Pacific Alliance of Rare Disease Organisation, Singapore Sonoko Misawa, associate professor, Chiba University Graduate School of Medicine, Japan Yukiko Nishimura, founder and president, NPO ASrid (Advocacy Service for Rare and Intractable Diseases’ Multi-Stakeholders in Japan) Min-Chieh Tseng, co-founder, Taiwan Foundation for Rare Diseases, Taiwan Gregory Vijayendran, chair, Rainbow Across Borders Richard Vines, chair, Rare Cancers Australia, Australia Jiaan-Der Wang, director of the Centre for Rare Diseases and Haemophilia, Taichung Veterans General Hospital, Taiwan Yi’ou Wang, secretary-general, Illness Challenge Foundation, China Chao-Chun Wu, deputy director general, Health Promotion Administration TaiwanThis research project was sponsored by CSL Behring. This report was written by Paul Kielstra and edited by Jesse Quigley Jones of The Economist Intelligence Unit.
Other language versions:
Snapshots:
Australia | China | Japan | Korea | Taiwan
无声的苦难:中国大陆罕见病的认知与管理评估
日本における希少疾患の現状: 認知度・QoL向上に向けた課題と取り組み
침묵 속의 고통: 한국의 희귀질환 인 식 및 관리현황 평가
無聲的苦難:評估台灣對於罕見疾病之認知與管理
Video highlights:
English | Simplified Chinese | Japanese | Korean | Traditional Chinese
Video | Suffering in silence report highlights
Suffering in Silence: Assessing rare-diseases awareness and management in Asia-Pacific
Full reports:
Snapshots:
Australia | China | Japan | Korea | Taiwan
无声的苦难:中国大陆罕见病的认知与管理评估
日本における希少疾患の現状: 認知度・QoL向上に向けた課題と取り組み
침묵 속의 고통: 한국의 희귀질환 인 식 및 관리현황 평가
無聲的苦難:評估台灣對於罕見疾病之認知與管理
Video highlights:
English | Simplified Chinese | Japanese | Korean | Traditional Chinese
Suffering in silence: Assessing rare disease awareness and management in Au...
In November-December 2019, The Economist Intelligence Unit surveyed 103 practising healthcare professionals from Australia, as part of an Asia-Pacific analysis of understanding and challenges faced in managing rare diseases.
Our survey respondents from Australia comprised general practitioners or primary care physicians (45.5%), specialist physicians (34.2%), nurses (8.0%) and pharmacists (12.3%). Respondents predominately worked in private (49.7%) and public or teaching healthcare institutions (46.5%).
Full reports:
Snapshots:
Australia | China | Japan | Korea | Taiwan
无声的苦难:中国大陆罕见病的认知与管理评估
日本における希少疾患の現状: 認知度・QoL向上に向けた課題と取り組み
침묵 속의 고통: 한국의 희귀질환 인 식 및 관리현황 평가
無聲的苦難:評估台灣對於罕見疾病之認知與管理
Video highlights:
English | Simplified Chinese | Japanese | Korean | Traditional Chinese
G20 countries are not prepared for the needs of ageing populations, according to new research from the Economist Intelligence Unit
Related content
The Cost of Silence: Cardiovascular disease in Asia
The Cost of Silence: Cardiovascular disease in Asia is a report by The Economist Intelligence Unit and EIU Healthcare. It provides a study of the economic impact of CVD risk factors on the following Asian markets: China, Australia, Hong Kong, Japan, Singapore, South Korea, Taiwan and Thailand.
Specifically, the study captures the cost of ischaemic heart disease (IHD) and stroke. IHD, also called coronary heart disease (CHD) or coronary artery disease, is the term given to heart problems caused by narrowed heart (coronary) arteries that supply blood to the heart muscle, which can lead to stable angina, unstable angina, myocardial infarctions or heart attacks, and sudden cardiac death. Stroke is characterised by the sudden loss of blood circulation to an area of the brain due to blockage of brain vessels, or a haemorrhage or blood clot.
This study further combines an evidence review of existing research on CVDs and primary research in the form of expert interviews.
Key findings of the report are as follow:
The rising incidence of CVD poses a substantial challenge to Asia-Pacific markets The four main modifiable cardiovascular risk factors pose a communications challenge for governments and health agencies. Hypertension is the risk factor that contributes the highest cost. The costs of CVDs are not fixed. Greater awareness and policymaker attention can substantially reduce CVD costs as many obstacles and corresponding solutions have been identified as effective. Policy options for primary prevention include choice “nudges”. Effective secondary prevention can also significantly affect costs and outcomes.The cost of inaction
The cost of inaction: Recognising the value at risk from climate change is a report by The Economist Intelligence Unit (The EIU). This research depicts the scope of assets at risk from climate change from the present to 2100. This innovative achievement draws on a modelling endeavour that combines The EIU’s long-term forecasts with a nuanced, integrated assessment model provided by Vivid Economics. The full methodology can be found in the appendix to this report which can be downloaded here for free. This white paper further discusses the possible consequences of climate change as well as how both investors and governments are measuring and responding to climate-related risks. The findings of this paper are based on detailed modelling, extensive desk research and interviews with a range of experts, conducted by The Economist Intelligence Unit.
To estimate the effect of climate change to 2100 on the changing stock of manageable financial assets, The Economist Intelligence Unit (The EIU) and Vivid Economics have used a leading, peer-reviewed forecasting model of the impact of climate change on the economy, the DICE (Dynamic Integrated Climate-Economy) model. DICE is one of a small number of integrated assessment models (IAMs) that have been built to estimate the economic cost of future climate change. These models link economic growth, greenhouse gas emissions, climate change and the damages from climate change back on the economy, and they do so in an integrated, consistent framework. They are typically built by adding a model of climate change to an existing framework for modelling the macroeconomy, with carbon emissions and climate damages providing the primary links between the two. DICE is the most popular of these models, having been used and cited in thousands of academic studies over nearly three decades.
The traditional purpose of IAMs has been to estimate the size of the climate change externality—the social cost of greenhouse gas emissions—in order to inform policymakers in setting emission targets or carbon prices. A famous example of such an exercise is the Stern Review, which estimated the present value of the future social costs of climate change to be equivalent to 5-20% of global GDP. The US Environmental Protection Agency has also recently used a suite of IAMs, including DICE, to determine the social costs of carbon for federal regulatory impact assessments. Since the value of financial assets is intrinsically linked to the performance of the economy, the innovation of this study is to use the DICE model to estimate the impact of climate change on financial assets instead.
This modelling recognises that, since the present value of a portfolio of equities should be the discounted cash flow of future dividends, then in the long run—ie, over the course of a century—dividends in a diversified portfolio should grow in line with GDP, as ultimately dividends are paid for from the output of the economy. In well-functioning financial markets the same relationship with GDP growth should hold for cash flows from other kinds of assets, such as bonds. This relationship may not be observed over a relatively long time period, even decades, owing to business cycles; for example, corporate profits are currently at historical highs, while GDP growth is low. However, on average, to 2100, this relationship can be expected to hold up. The DICE model is then used to forecast the effect of climate change on GDP, and in turn on cash flows from assets. The results are for total global assets as DICE is a globally aggregated model that does not allow explicit disaggregation by asset class or by region.
Value-based healthcare in Sweden: Reaching the next level
The need to get better value from healthcare investment has never been more important as ageing populations and increasing numbers of people with multiple chronic conditions force governments to make limited financial resources go further.
These pressures, along with a greater focus on patient-centred care, have raised the profile of VBHC, especially in European healthcare systems. Sweden, with its highly comprehensive and egalitarian healthcare system, has been a leader in implementing VBHC from the beginning, a fact that was underscored in a 2016 global assessment of VBHC published by The Economist Intelligence Unit.
This paper looks at the ways in which Sweden has implemented VBHC, the areas in which it has faced obstacles and the lessons that it can teach other countries and health systems looking to improve the value of their own healthcare investments.
Video | Suffering in silence report highlights - Simplified Chinese
Related content
Suffering in silence: Assessing rare disease awareness and management in As...
As the region begins to get to grips with rare diseases, it will need to address significant challenges, some of which are still emerging. Health and social systems are making progress in many of these areas, but finding solutions remains a work in progress.
This Economist Intelligence Unit study, sponsored by CSL Behring, looks at the nature of the rare disease challenge in the region, how prepared five of its economies are to face it, and reviews the initiatives aiming to provide better care. It draws on a substantial survey of over 500 clinicians, interviews with 16 academic, medical, government and patient experts, and extensive desk research.
In November-December 2019, The Economist Intelligence Unit surveyed 503 healthcare professionals across five Asia-Pacific markets to gauge their understanding of rare diseases and identify the challenges faced by national health systems. Respondents comprised currently practicing specialist physicians (n=172), general practitioners (n=229), nurses (n=40) and pharmacists (n=62). Markets included were Australia (n=103), China (n=100), Japan (n=100), South Korea (n=100) and Taiwan (n=100).
In addition, in-depth contextualising interviews were conducted with 16 expert representatives of clinical practice and patient organisations to inform our research programme and this report. Our sincerest thanks go to the following for their time and insight:
Takeya Adachi, program officer, Agency for Medical Research and Development, Japan Younjhin Ahn, Division of Rare Diseases, Korean National Institute of Health Centre for Biomedical Sciences, South Korea Matthew Bellgard, professor and director of eResearch, Queensland University of Technology, Australia and chair of the Asia Pacific Economic Cooperation (APEC) Rare Disease Network, Australia Gareth Baynam, clinical geneticist and director of the Undiagnosed Diseases Program Genetic Services of Western Australia, Australia Dong Dong, research assistant professor, Chinese University of Hong Kong, Hong Kong SAR Elizabeth Elliott, professor of Paediatrics and Child Health, University of Sydney, Australia Kevin Huang, founder, Chinese Organization for Rare Disorders, China Ritu Jain, president, Asia-Pacific Alliance of Rare Disease Organisation, Singapore Sonoko Misawa, associate professor, Chiba University Graduate School of Medicine, Japan Yukiko Nishimura, founder and president, NPO ASrid (Advocacy Service for Rare and Intractable Diseases’ Multi-Stakeholders in Japan) Min-Chieh Tseng, co-founder, Taiwan Foundation for Rare Diseases, Taiwan Gregory Vijayendran, chair, Rainbow Across Borders Richard Vines, chair, Rare Cancers Australia, Australia Jiaan-Der Wang, director of the Centre for Rare Diseases and Haemophilia, Taichung Veterans General Hospital, Taiwan Yi’ou Wang, secretary-general, Illness Challenge Foundation, China Chao-Chun Wu, deputy director general, Health Promotion Administration TaiwanThis research project was sponsored by CSL Behring. This report was written by Paul Kielstra and edited by Jesse Quigley Jones of The Economist Intelligence Unit.
Other language versions:
Snapshots:
Australia | China | Japan | Korea | Taiwan
无声的苦难:中国大陆罕见病的认知与管理评估
日本における希少疾患の現状: 認知度・QoL向上に向けた課題と取り組み
침묵 속의 고통: 한국의 희귀질환 인 식 및 관리현황 평가
無聲的苦難:評估台灣對於罕見疾病之認知與管理
Video highlights:
English | Simplified Chinese | Japanese | Korean | Traditional Chinese
Suffering in silence: Assessing rare disease awareness and management in Au...
In November-December 2019, The Economist Intelligence Unit surveyed 103 practising healthcare professionals from Australia, as part of an Asia-Pacific analysis of understanding and challenges faced in managing rare diseases.
Our survey respondents from Australia comprised general practitioners or primary care physicians (45.5%), specialist physicians (34.2%), nurses (8.0%) and pharmacists (12.3%). Respondents predominately worked in private (49.7%) and public or teaching healthcare institutions (46.5%).
Full reports:
Snapshots:
Australia | China | Japan | Korea | Taiwan
无声的苦难:中国大陆罕见病的认知与管理评估
日本における希少疾患の現状: 認知度・QoL向上に向けた課題と取り組み
침묵 속의 고통: 한국의 희귀질환 인 식 및 관리현황 평가
無聲的苦難:評估台灣對於罕見疾病之認知與管理
Video highlights:
English | Simplified Chinese | Japanese | Korean | Traditional Chinese
Suffering in silence: Assessing rare disease awareness and management in So...
In November-December 2019, The Economist Intelligence Unit surveyed 100 practising healthcare professionals from South Korea, as part of an Asia-Pacific analysis of understanding and challenges faced in managing rare diseases.
Our survey respondents from South Korea comprised general practitioners or primary care physicians (45%), specialist physicians (35%), nurses (10%) and pharmacists (10%). Respondents reported working in predominantly private (58%) and public (12%) or teaching healthcare institutions (25%).
Full reports:
Snapshots:
Australia | China | Japan | Korea | Taiwan
无声的苦难:中国大陆罕见病的认知与管理评估
日本における希少疾患の現状: 認知度・QoL向上に向けた課題と取り組み
침묵 속의 고통: 한국의 희귀질환 인 식 및 관리현황 평가
無聲的苦難:評估台灣對於罕見疾病之認知與管理
Video highlights:
English | Simplified Chinese | Japanese | Korean | Traditional Chinese
Video | Suffering in silence report highlights - Korean
Related content
Suffering in silence: Assessing rare disease awareness and management in As...
As the region begins to get to grips with rare diseases, it will need to address significant challenges, some of which are still emerging. Health and social systems are making progress in many of these areas, but finding solutions remains a work in progress.
This Economist Intelligence Unit study, sponsored by CSL Behring, looks at the nature of the rare disease challenge in the region, how prepared five of its economies are to face it, and reviews the initiatives aiming to provide better care. It draws on a substantial survey of over 500 clinicians, interviews with 16 academic, medical, government and patient experts, and extensive desk research.
In November-December 2019, The Economist Intelligence Unit surveyed 503 healthcare professionals across five Asia-Pacific markets to gauge their understanding of rare diseases and identify the challenges faced by national health systems. Respondents comprised currently practicing specialist physicians (n=172), general practitioners (n=229), nurses (n=40) and pharmacists (n=62). Markets included were Australia (n=103), China (n=100), Japan (n=100), South Korea (n=100) and Taiwan (n=100).
In addition, in-depth contextualising interviews were conducted with 16 expert representatives of clinical practice and patient organisations to inform our research programme and this report. Our sincerest thanks go to the following for their time and insight:
Takeya Adachi, program officer, Agency for Medical Research and Development, Japan Younjhin Ahn, Division of Rare Diseases, Korean National Institute of Health Centre for Biomedical Sciences, South Korea Matthew Bellgard, professor and director of eResearch, Queensland University of Technology, Australia and chair of the Asia Pacific Economic Cooperation (APEC) Rare Disease Network, Australia Gareth Baynam, clinical geneticist and director of the Undiagnosed Diseases Program Genetic Services of Western Australia, Australia Dong Dong, research assistant professor, Chinese University of Hong Kong, Hong Kong SAR Elizabeth Elliott, professor of Paediatrics and Child Health, University of Sydney, Australia Kevin Huang, founder, Chinese Organization for Rare Disorders, China Ritu Jain, president, Asia-Pacific Alliance of Rare Disease Organisation, Singapore Sonoko Misawa, associate professor, Chiba University Graduate School of Medicine, Japan Yukiko Nishimura, founder and president, NPO ASrid (Advocacy Service for Rare and Intractable Diseases’ Multi-Stakeholders in Japan) Min-Chieh Tseng, co-founder, Taiwan Foundation for Rare Diseases, Taiwan Gregory Vijayendran, chair, Rainbow Across Borders Richard Vines, chair, Rare Cancers Australia, Australia Jiaan-Der Wang, director of the Centre for Rare Diseases and Haemophilia, Taichung Veterans General Hospital, Taiwan Yi’ou Wang, secretary-general, Illness Challenge Foundation, China Chao-Chun Wu, deputy director general, Health Promotion Administration TaiwanThis research project was sponsored by CSL Behring. This report was written by Paul Kielstra and edited by Jesse Quigley Jones of The Economist Intelligence Unit.
Other language versions:
Snapshots:
Australia | China | Japan | Korea | Taiwan
无声的苦难:中国大陆罕见病的认知与管理评估
日本における希少疾患の現状: 認知度・QoL向上に向けた課題と取り組み
침묵 속의 고통: 한국의 희귀질환 인 식 및 관리현황 평가
無聲的苦難:評估台灣對於罕見疾病之認知與管理
Video highlights:
English | Simplified Chinese | Japanese | Korean | Traditional Chinese
Suffering in silence: Assessing rare disease awareness and management in Ta...
In November-December 2019, The Economist Intelligence Unit surveyed 100 practising healthcare professionals from Taiwan, as part of an Asia-Pacific analysis of understanding and challenges faced in managing rare diseases.
Our survey respondents from Taiwan comprised general practitioners or primary care physicians (46%), specialist physicians (34%), nurses (10%) and pharmacists (10%). Respondents were split between private (54.0%) and public (21%) or teaching healthcare institutions (25%).
Full reports:
Snapshots:
Australia | China | Japan | Korea | Taiwan
无声的苦难:中国大陆罕见病的认知与管理评估
日本における希少疾患の現状: 認知度・QoL向上に向けた課題と取り組み
침묵 속의 고통: 한국의 희귀질환 인 식 및 관리현황 평가
無聲的苦難:評估台灣對於罕見疾病之認知與管理
Video highlights:
English | Simplified Chinese | Japanese | Korean | Traditional Chinese
Suffering in silence: Assessing rare disease awareness and management in Ja...
In November-December 2019, The Economist Intelligence Unit surveyed 100 practising healthcare professionals from Japan, as part of an Asia-Pacific analysis of understanding and challenges faced in managing rare diseases.
Our survey respondents from Japan comprised general practitioners or primary care physicians (44%), specialist physicians (35%), nurses (6%) and pharmacists (14%). The majority of respondents reported working in private (64%) and public or teaching healthcare institutions (16%).
Full reports:
Snapshots:
Australia | China | Japan | Korea | Taiwan
无声的苦难:中国大陆罕见病的认知与管理评估
日本における希少疾患の現状: 認知度・QoL向上に向けた課題と取り組み
침묵 속의 고통: 한국의 희귀질환 인 식 및 관리현황 평가
無聲的苦難:評估台灣對於罕見疾病之認知與管理
Video highlights:
English | Simplified Chinese | Japanese | Korean | Traditional Chinese